Improvements in hepatitis B virus screening before rituximab therapy: A community-based, safety-net hospital experience.
Kevin JunusMaria AguilarPriya PatelDavid IrwinStephen YeeBenny LiuTaft BhuketRobert J WongPublished in: Cancer (2016)
Among adults receiving RTX therapy in a single community-based hospital system, HBV screening rates were suboptimal, and 28.6% of HBsAg-positive patients and 7.4% of HBsAg-negative/HBcAb-positive patients who did not receive antiviral treatment experienced HBV reactivation or flare. Cancer 2017;123:650-656. © 2016 American Cancer Society.
Keyphrases
- hepatitis b virus
- papillary thyroid
- liver failure
- end stage renal disease
- squamous cell
- healthcare
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- diffuse large b cell lymphoma
- emergency department
- childhood cancer
- squamous cell carcinoma
- patient reported outcomes
- young adults
- combination therapy
- cell therapy
- bone marrow